Reactogenicity and Immunogenicity of the ChAdOx1 nCOV-19 Coronavirus Disease 2019 Vaccine in South Korean Healthcare Workers
2
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Purpose: The association between reactogenicity and immunogenicity of the ChAdOx1 nCOV-19 is controversial. We aimed to evaluate this association among South Korean healthcare workers (HCWs). Materials and Methods: Participants received two doses of the ChAdOx1vaccine 12 weeks apart. Blood samples were tested for anti-severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) spike protein receptor binding domain antibodies about 2 months after the first and second doses using the Elecsys Anti-SARS-CoV-2 S assay kits. Adverse events were noted using an online self-reporting questionnaire. Results: Among the 232 HCWs, pain (85.78% after the first dose vs. 58.62% after the second dose, p<0.001) was the most prominent local reaction, and myalgia or fatigue (84.05% vs. 53.02%, p<0.001) was the most prominent systemic reaction. The frequency of all adverse events was significantly reduced after the second dose. After the first dose, the anti-SARS-CoV-2 S showed significantly higher titer in the group with swelling, itching, fever, and nausea. Also, the anti-SARS-CoV-2 S titer significantly increased as the grade of fever (p=0.007) and duration of fever (p=0.026) increased; however, there was no significant correlation between immunogenicity and adverse event after the second dose. The group with pain after the first dose showed a greater increase in the anti-SARS-CoV-2 S difference between the second and first doses compared to the group without pain (542.2 U/mL vs. 363.8 U/mL, p=0.037). Conclusion: The frequency of adverse events occurring after the first dose of the ChAdOx1 was significantly reduced after the second dose. Interestingly, the elevation of anti-SARS-CoV-2 S titer was significantly increased in the group with pain after the first dose.
Abstract
Purpose: The association between reactogenicity and immunogenicity of the ChAdOx1 nCOV-19 is controversial. We aimed to evaluate this association among South Korean healthcare workers (HCWs). Materials and Methods: Participants received two doses of the ChAdOx1vaccine 12 weeks apart. Blood samples were tested for anti-severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) spike protein receptor binding domain antibodies about 2 months after the first and second doses using the Elecsys Anti-SARS-CoV-2 S assay kits. Adverse events were noted using an online self-reporting questionnaire. Results: Among the 232 HCWs, pain (85.78% after the first dose vs. 58.62% after the second dose, p<0.001) was the most prominent local reaction, and myalgia or fatigue (84.05% vs. 53.02%, p<0.001) was the most prominent systemic reaction. The frequency of all adverse events was significantly reduced after the second dose. After the first dose, the anti-SARS-CoV-2 S showed significantly higher titer in the group with swelling, itching, fever, and nausea. Also, the anti-SARS-CoV-2 S titer significantly increased as the grade of fever (p=0.007) and duration of fever (p=0.026) increased; however, there was no significant correlation between immunogenicity and adverse event after the second dose. The group with pain after the first dose showed a greater increase in the anti-SARS-CoV-2 S difference between the second and first doses compared to the group without pain (542.2 U/mL vs. 363.8 U/mL, p=0.037). Conclusion: The frequency of adverse events occurring after the first dose of the ChAdOx1 was significantly reduced after the second dose. Interestingly, the elevation of anti-SARS-CoV-2 S titer was significantly increased in the group with pain after the first dose.
참고문헌 (27)
- [URL]
- Bar-On YM, "Protection by a fourth dose of BNT162b2 against Omicron in Israel", N Engl J Med, 386, pp.1712~1720 (2022)
- de Gier B, "Vaccine effectiveness against SARS-CoV-2transmission and infections among household and other close contacts of confirmed cases, the Netherlands, February to May 2021", Euro Surveill, 26, pp.2100640~ (2021)
- Singanayagam A, "Community transmission and viral load kinetics of the SARS-CoV-2 delta(B. 1. 617. 2)variant in vaccinated and unvaccinated individuals in the UK : a prospective, longitudinal, cohort study", Lancet Infect Dis, 22, pp.183~195 (2022)
- Voysey M, "Safety and efficacy of the ChAdOx1 nCoV-19 vaccine(AZD1222)against SARS-CoV-2 : an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK", Lancet, 397, pp.99~111 (2021)
- Voysey M, "Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19(AZD1222)vaccine : a pooled analysis of four randomised trials", Lancet, 397, pp.881~891 (2021)
- Falsey AR, "Phase 3 safety and efficacy of AZD1222(ChAdOx1 nCoV-19)Covid-19 vaccine", N Engl J Med, 385, pp.2348~2360 (2021)
- Hervé C, "The how’s and what’s of vaccine reactogenicity", NPJ Vaccines, 4, pp.39~ (2019)
- Young Hoon Hwang, "Can reactogenicity predict immunogenicity after COVID-19 vaccination?", The Korean Journal of Internal Medicine, 36(6), pp.1486~1491 (2021), 대한내과학회[DOI]
- Food and Drug Administration, "Toxicity grading scale for healthy adult and adolescent volunteers enrolled in preventive vaccine clinical trials: guidance for industry" (2007), Food and Drug Administration
- Greinacher A, "Thrombotic thrombocytopenia after ChAdOx1 nCov-19vaccination", N Engl J Med, 384, pp.2092~2101 (2021)
- Ramasamy MN, "Safety and immunogenicity of ChAdOx1nCoV-19 vaccine administered in a prime-boost regimen in young and old adults(COV002) : a single-blind, randomised, controlled, phase 2", 3 trial, 2020, pp.396, 1979~1993
- Bae Seongman, "Adverse Reactions Following the First Dose of ChAdOx1 nCoV-19 Vaccine and BNT162b2 Vaccine for Healthcare Workers in South Korea", Journal of Korean Medical Science, 36(17), pp.1~9 (2021), 대한의학회[DOI]
- Schmidt T, "Immunogenicity and reactogenicity of heterologous ChAdOx1nCoV-19", mRNA vaccination, 2021, pp.27, 1530~1535
- Flaxman A, "Reactogenicity and immunogenicity after a late second dose or a third dose of ChAdOx1 nCoV-19 in the UK : a substudy of two randomised controlled trials(COV001 and COV002)", Lancet, 398, pp.981~990 (2021)
- Normark J, "Heterologous ChAdOx1 nCoV-19 and mRNA-1273 vaccination", N Engl J Med, 385, pp.1049~1051 (2021)
- Zhuang CL, "Inflammation-related adverse reactions following vaccination potentially indicate a stronger immune response", Emerg Microbes Infect, 10, pp.365~375 (2021)
- Burny W, "Inflammatory parameters associated with systemic reactogenicity following vaccination with adjuvanted hepatitis B vaccines in humans", Vaccine, 37, pp.2004~2015 (2019)
- Lee SW, "Anti-SARS-CoV-2 spike protein RBD antibody levels after receiving a second dose of ChAdOx1 nCov-19(AZD1222)vaccine in healthcare workers : lack of association with age, sex, obesity, and adverse reactions", Front Immunol, 12, pp.779212~ (2021)
- Coggins SAA, "Adverse effects and antibody titers in response to the BNT162b2 mRNA COVID-19 vaccine in a prospective study of healthcare workers", Open Forum Infect Dis, 9, pp.ofab575~ (2022)
- Takeuchi M, "Does reactogenicity after a second injection of the BNT162b2 vaccine predict spike IgG antibody levels in healthy Japanese subjects", PLoS One, 16, pp.e0257668~ (2021)
- Jalkanen P, "COVID-19 mRNA vaccine induced antibody responses against three SARS-CoV-2 variants", Nat Commun, 12, pp.3991~ (2021)
- Park JY, "Systemic adverse events and use of antipyretics predict the neutralizing antibody positivity early after the first dose of chadox1 coronavirus disease vaccine", J Clin Med, 10, pp.2844~ (2021)
- 임소윤, "Correlation between Reactogenicity and Immunogenicity after the ChAdOx1 nCoV-19 and BNT162b2 mRNA Vaccination", Immune Network, 21(6), pp.1~13 (2021), 대한면역학회[DOI]
- Yamamoto S, "Association between reactogenicity and SARS-CoV-2 antibodies after the second dose of the BNT162b2 COVID-19 vaccine", Vaccine, 40, pp.1924~1927 (2022)
- Koike R, "Systemic adverse effects induced by the BNT162b2vaccine are associated with higher antibody titers from 3 to 6months after vaccination", Vaccines, 10, pp.451~ (2022)
- Naaber P, "Dynamics of antibody response to BNT162b2 vaccine after six months : a longitudinal prospective study", Lancet Reg Health Eur, 10, pp.100208~ (2021)